ReNAgade Therapeutics

ReNAgade Therapeutics

Biotechnology firm specializing in RNA medicine

About ReNAgade Therapeutics

Simplify's Rating
Why ReNAgade Therapeutics is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series A

Total Funding

$300M

Headquarters

Cambridge, Massachusetts

Founded

2021

Overview

ReNAgade Therapeutics focuses on developing RNA medicines to address the challenges of delivering therapies to specific tissues and creating a comprehensive treatment platform. The company has created a unique toolkit that enables precise correction of diseases on a large scale. By utilizing proprietary delivery technologies, ReNAgade can access previously unreachable cells and enhance gene expression through a collaboration with Orna Therapeutics. Unlike traditional gene therapy, which typically replaces defective genes, ReNAgade's approach aims to permanently correct faulty genes, allowing for more effective curative therapies. This technology also supports the insertion of larger genes or exons, making ReNAgade a leader in the next generation of gene therapy. The company serves clients in the medical and healthcare sectors, generating revenue through joint ventures, licensing its technologies, and potentially developing its own therapeutic products.

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in RNA therapies boosts ReNAgade's growth potential.
  • Advancements in LNP technology complement ReNAgade's RNA delivery systems.
  • FDA approvals of RNA therapies may streamline ReNAgade's regulatory pathway.

What critics are saying

  • Orna's acquisition may lead to strategic shifts affecting ReNAgade's projects.
  • Previous layoffs at Orna raise concerns about potential instability post-acquisition.
  • Integration of GanNA Bio's technology may delay new RNA medicine development.

What makes ReNAgade Therapeutics unique

  • ReNAgade Therapeutics offers a unique all-RNA system for gene correction and insertion.
  • The company collaborates with Orna Therapeutics to enhance RNA delivery technologies.
  • ReNAgade's proprietary toolkit allows precise disease correction on a large scale.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$300M

Above

Industry Average

Funded Over

1 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$30M
Kalshi
$300M
ReNAgade Therapeutics

Company News

PR Newswire
May 23rd, 2024
Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies

/PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics...

BioPharma Dive
May 23rd, 2024
Orna, a circular RNA specialist, acquires a buzzy startup

After laying off staff late last year, Orna is now expanding through the purchase of ReNAgade Therapeutics, which was built around technology designed to more effectively deliver RNA-based medicines.

Business Wire
Apr 29th, 2024
Correcting And Replacing Renagade Therapeutics Continues Commitment To Ganna Bio And Glycan Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads:. RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY

Business Wire
Apr 27th, 2024
Renagade Therapeutics Setzt Engagement Für Ganna Bio Und Glykobiologie Fort

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--ReNAgade Therapeutics, ein Unternehmen, das das grenzenlose Potenzial von RNA-Medikamenten erschließt, gab heute sein anhaltendes Engagement für die Erforschung der therapeutischen Möglichkeiten der Glykobiologie durch die Unterstützung der laufenden Forschung bei GanNA Bio und die Integration von Schlüsselpersonen von GanNA Bio in das Ökosystem von ReNAgade bekannt. Die Gründer von GanNA, Carolyn Bertozzi, Ph.D., und Richard D. Cummings, Ph.D., werden fortan als Berater von ReNAgade fungieren. „ReNAgade wird weiterhin enorm von der vielversprechenden Arbeit von GanNA profitieren, insbesondere in Bezug auf die Entwicklung einer Technologie zur extrahepatischen Verabreichung, die dazu beiträgt, den Umfang und das Potenzial unserer eigenen RNA-Medikamente zu erweitern“, sagte Brian Goodman, Mitbegründer von ReNAgade. „Die Verabreichung ist grundlegend für die Mission von ReNAgade, die aktuellen Einschränkungen von RNA-Medikamenten zu überwinden. Wir glauben, dass die innerhalb von GanNA entwickelte Technologie dazu beitragen wird, die führende Position von ReNAgade weiter zu festigen, während wir unsere einzigartige, integrierte therapeutische Plattform weiter vorantreiben.“

Business Wire
Apr 27th, 2024
Renagadeセラピューティクス、Ganna Bioと糖鎖生物学に対するコミットメントを継続

米マサチューセッツ州ケンブリッジ--(BUSINESS WIRE)--(ビジネスワイヤ) --. RNA医薬品の無限の可能性にチャレンジする企業であるReNAgadeセラピューティクスは、GanNA Bioで現在進めている研究を支援し、同社のキーパーソンをReNAgadeのエコシステムに迎え入れることで、糖鎖生物学を活用した治療機会の探求に継続的に取り組むことを発表しました。GanNAの創設者であるキャロライン・ベルトッツィ博士とリチャード・D・カミングス博士は、今後ReNAgadeのアドバイザーを務めることになります。. 「GanNAが開発している肝外送達技術はReNAgade独自のRNA医薬品の幅と可能性を広げてくれます。当社はこうしたGanNAの将来有望な研究から、今後も多大な恩恵を受けることになるでしょう」と、ReNAgadeの共同創設者であるブライアン・グッドマンは述べています。「送達技術は、現在のRNA医薬品の限界を克服するというReNAgadeの使命の土台となるものです。GanNAが開発した技術により、ReNAgadeのリーダーとしての地位はさらに強固なものとなり、当社独自の統合治療プラットフォームはさらに発展すると確信しています。」

There are no jobs for ReNAgade Therapeutics right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →